Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal Guam.
Press releases published on July 9, 2025
Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
GlobeNewswire
·
July 9, 2025
SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today …
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 9, 2025
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell …
New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials
GlobeNewswire
·
July 9, 2025
Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE’s Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a …
Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
GlobeNewswire
·
July 9, 2025
NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
GlobeNewswire
·
July 9, 2025
Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services …
Dr. Anosh Ahmed Plans $25,000 Donation to Support FBI Families and Law Enforcement Mental Health Programs
GlobeNewswire
·
July 9, 2025
Image by Dr. Anosh Ahmed CHICAGO, July 09, 2025 (GLOBE NEWSWIRE) -- Dr. Anosh Ahmed, a Chicago-based physician and founder of the Anosh Inc Foundation, has announced plans to donate $25,000 to nonprofit organizations that support FBI agents and their …
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
GlobeNewswire
·
July 9, 2025
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 ( …
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
GlobeNewswire
·
July 9, 2025
PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire
·
July 9, 2025
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 ( …
BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
GlobeNewswire
·
July 9, 2025
CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver …
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
GlobeNewswire
·
July 9, 2025
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate …
FluidForm Bio™ Presents Six-Month Efficacy Data of FRESH 3D Bioprinted Human Islet Subcutaneous Scaffolds at the American Diabetes Association (ADA) 85th Scientific Sessions
GlobeNewswire
·
July 9, 2025
WALTHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced two presentations at recent medical meetings: the 20th World Congress of the International Pancreas …
TerrAscend Completes $79 Million Non-Dilutive Debt Financing
GlobeNewswire
·
July 9, 2025
Proceeds used to retire $68 million of existing debt with the remainder designated for future growth initiatives Additional facility of up to $35 million available for strategic M…
Amneal to Report Second Quarter 2025 Results on August 5, 2025
GlobeNewswire
·
July 9, 2025
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial results on …
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026
GlobeNewswire
·
July 9, 2025
NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension …
CoRegen, Inc. Closes More Than $93 Million Financing
GlobeNewswire
·
July 9, 2025
HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, today announced the close of a $93,390,000 million financing. The proceeds …
Benitec Biopharma Provides Operational Updates
GlobeNewswire
·
July 9, 2025
-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects …
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
GlobeNewswire
·
July 9, 2025
KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation …
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
GlobeNewswire
·
July 9, 2025
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its …
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
GlobeNewswire
·
July 9, 2025
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-lasting …